China Universal Asset Management Company’s Autolus Therapeutics AUTL Stock Holding History

China Universal Asset Management Company’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.1K	Sell	31,925 -3,672	-10%	-$5.76K	﹤0.01%	460
2026 Q1	$49.1K	Buy	35,597 +2,910	+9%	+$4.42K	﹤0.01%	457
2025 Q4	$65K	Sell	32,687 -2,470	-7%	-$3.79K	0.01%	438
2025 Q3	$57.3K	Sell	35,157 -5,116	-13%	-$9.99K	﹤0.01%	424
2025 Q2	$91.8K	Buy	40,273 +73	+0.2%	+$121	0.01%	373
2025 Q1	$62.3K	Sell	40,200 -2,145	-5%	-$4.35K	0.01%	397
2024 Q4	$99.5K	Buy	42,345 +3,952	+10%	+$13.4K	0.01%	391
2024 Q3	$139K	Buy	38,393 +14,959	+64%	+$59.7K	0.02%	327
2024 Q2	$81.5K	Sell	23,434 -3,600	-13%	-$15.5K	0.01%	313
2024 Q1	$172K	Buy	27,034 +10,771	+66%	+$67.2K	0.02%	311
2023 Q4	$105K	Buy	+16,263	New	+$62K	0.02%	273
2022 Q4	–	Sell	-542	Closed	-$1K	–	400
2022 Q3	$1K	Buy	+542	New	+$1.61K	﹤0.01%	382

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

China Universal Asset Management Company's AUTL Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Autolus Therapeutics (AUTL) stake by 10% in Q2 2026, selling an estimated $5.76K and leaving 31,925 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

China Universal Asset Management Company first reported a position in AUTL in Q3 2022 and has held it in 12 quarters since. The position peaked at $172K in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

China Universal Asset Management Company held 31,925 shares of Autolus Therapeutics worth $51.1K as of Q2 2026.
China Universal Asset Management Company sold 3,672 Autolus Therapeutics shares in Q2 2026, an estimated $5.76K.
Autolus Therapeutics made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #460 holding.
China Universal Asset Management Company first reported a position in Autolus Therapeutics in Q3 2022 and has held it in 12 quarters since.
China Universal Asset Management Company's Autolus Therapeutics position peaked at $172K in Q1 2024.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.